# Ad hoc release

Ad-hoc-release pursuant to Art. 17 MAR

## European Commission extends Ameluz® approval to basal cell carcinoma

Leverkusen, Germany, January 30, 2017 – Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, announces today that the European Commission has followed the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and has granted approval extension for Ameluz® to basal cell carcinoma. The extended approval includes the treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults.

The Management Board

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611

contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
e-mail: press@biofrontera.com